Back

HER2 overexpression initiates breast tumorigenesis non-cell-autonomously by inducing oxidative stress in the tissue microenvironment

Gurler, S. B.; Wagstaff, O.; Dimitrova, L.; Chen, F.; Pedley, R.; Weston, W.; Donaldson, I.; Telfer, B. A.; Novo, D.; Pavlou, K.; Taylor, G.; Ou, Y.; Williams, K. J.; Gilmore, A. P.; Brennan, K.; Ucar, A.

2023-08-27 cancer biology
10.1101/2023.08.25.554770 bioRxiv
Show abstract

HER2 is considered as a driver oncogene responsible for the HER2+ subtype of breast cancer. However, it is still unclear how HER2 induces the oncogenic transformation of breast cancer stem cells (BCSCs) and initiates tumorigenesis during premalignant stage breast cancer. Here, we used clinical samples and mouse models of HER2+ breast cancer to demonstrate that neither BCSCs nor their cell-of-origin express HER2/Neu in early-stage breast tumors. Instead, our results demonstrate that Neu overexpression results in the transformation of BCSCs in a non-cell-autonomous manner via triggering DNA damage and somatic mutagenesis in their Neu-negative cell-of-origin. This is caused by the increased oxidative stress in the tissue microenvironment generated by altered energy metabolism and increased reactive oxygen species levels in Neu-overexpressing mammary ducts. Therefore, our findings illustrate a previously unrecognized mechanism of HER2-induced breast tumor initiation in vivo with potential impacts on future preventive treatments for HER2+ premalignant breast cancer.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Cell Death & Disease
126 papers in training set
Top 0.1%
22.6%
2
Cancers
200 papers in training set
Top 0.3%
10.5%
3
Scientific Reports
3102 papers in training set
Top 18%
6.4%
4
Cell Death Discovery
51 papers in training set
Top 0.2%
3.6%
5
Cell Reports
1338 papers in training set
Top 14%
3.6%
6
Nature Communications
4913 papers in training set
Top 39%
3.6%
50% of probability mass above
7
Oncogene
76 papers in training set
Top 0.6%
3.3%
8
Cancer Research
116 papers in training set
Top 1%
3.1%
9
International Journal of Cancer
42 papers in training set
Top 0.4%
2.6%
10
PLOS ONE
4510 papers in training set
Top 46%
2.4%
11
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 3%
2.1%
12
BMC Cancer
52 papers in training set
Top 1%
1.8%
13
Breast Cancer Research
32 papers in training set
Top 0.3%
1.8%
14
Advanced Science
249 papers in training set
Top 10%
1.8%
15
Redox Biology
64 papers in training set
Top 0.4%
1.7%
16
eLife
5422 papers in training set
Top 42%
1.7%
17
Molecular Oncology
50 papers in training set
Top 0.5%
1.3%
18
Cells
232 papers in training set
Top 3%
1.3%
19
iScience
1063 papers in training set
Top 22%
1.2%
20
Communications Biology
886 papers in training set
Top 17%
1.0%
21
Neoplasia
22 papers in training set
Top 0.5%
0.9%
22
Cancer Letters
32 papers in training set
Top 0.7%
0.8%
23
International Journal of Molecular Sciences
453 papers in training set
Top 15%
0.7%
24
Theranostics
33 papers in training set
Top 1%
0.7%
25
Translational Oncology
18 papers in training set
Top 0.4%
0.7%
26
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.3%
0.7%
27
Frontiers in Oncology
95 papers in training set
Top 4%
0.7%
28
Metabolism
14 papers in training set
Top 0.6%
0.6%
29
Molecular Cancer Research
42 papers in training set
Top 0.9%
0.6%
30
NAR Cancer
36 papers in training set
Top 0.2%
0.6%